Facebook
Twitter
LinkedIn
ForwardIn Conversation with the Neighborhood Hepatologist: Practical Strategies for Improving Recognition and Risk Stratification of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD), Webinar 6/25/2024
Nonalcoholic fatty liver disease (NAFLD) or fatty liver is the most common cause for chronic liver disease in the US and is a significant public health concern. It is estimated that 1 in 3 American adults have fatty liver. Among people with fatty liver, 20-30% progress to metabolic dysfunction-associated steatotic liver disease (MASLD), a condition characterized by injury and inflammation in liver cells, which can eventually lead to advanced fibrosis, cirrhosis, and liver cancer. It is estimated that 5% of the US population has MASLD.
In the US, rates of NAFLD are projected to increase from 83.1 and 16.52 million (2015) to 100.9 million and 27 million by 2030, respectively. It is therefore crucial to increase awareness about fatty liver and re-enforce patient care pathways to combat the growing burden of this condition, particularly for vulnerable populations and those at higher risk.
The overall goal of this program is to address these gaps to improve how MASLD is currently screened, diagnosed, and managed. Specifically, we will focus on how primary care professionals (PCPs) can collaborate with other specialist clinicians to better identify patients at risk of developing MASLD and optimize care.
Target Audience
This activity has been designed to meet the educational needs of primary care physicians, nurses and family practitioners.
Learning Objectives
At the conclusion of this activity participants will be better able to:
- Recognize the current disease burden of MASLD.
- Explain patient perspectives on MASLD.
- Describe noninvasive tests for identifying patients with MASLD, and those at high risk for clinically significant liver fibrosis who would also warrant potential therapy.
- Describe evidence-based management for patients with MASLD and at-risk fibrosis.
- Discuss tips for implementing evidence-based recommendations for management of MASLD into daily practice.
Additional Information
| Attachment | Size |
|---|---|
 MASLD Slides 6.25.24 | 2.86 MB |
Speakers
Arpan Mohanty, MD, MSc
Program Course Director
Staff Hepatologist, Boston Medical Center
Assistant Professor of Medicine, Boston University Chobanian & Avedisian School of Medicine
Boston, MA
Juhee C. McDougal, MD
Primary Care Provider/Internist
Department of Medicine, Boston Medical Center
Assistant Professor of Medicine , Boston University Chobanian & Avedisian School of Medicine
Boston, MA
Accreditor Disclosure Policy
Boston University Chobanian and Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian and Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
Program Faculty Disclosures
Dr. Mohanty has received grant research support from Gilead and Inventiva and has been a consultant for Novo Nordisk. She is also an investigator for Intercept, Inventiva, Novo Nordisk, Madrigal and Takeda.
Dr. McDougal, planning committee member and speaker, has no relevant financial relationships to disclose.
Off-Label Discussion
The faculty members do not plan on discussing unlabeled/investigational uses of a commercial product.
Accreditor Disclosures
The following planning committee members from Boston University Chobanian and Avedisian School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships to disclose:
Michael Burk, BS – Senior Program Manager
Jessica Bocook, MD – American Academy of Family Physician (AAFP) and CME Accreditation Reviewer
Disclaimer
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.
Joint Accreditation
In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
The Boston University Chobanian & Avedisian School of Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
Nursing Contact Hours: 1, all of which is eligible for pharmacology credit.
American Academy of Family Physicians (AAFP) Accreditation
The AAFP has reviewed In Conversation with the Neighborhood Hepatologist: Practical Strategies for Improving Recognition and Risk Stratification of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) and deemed it acceptable for up to 1.00 Live AAFP Prescribed credit(s). Term of Approval is from 06/25/2024 to 06/25/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AAFP Prescribed
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this Live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ANCC
- 1.00 ANCC Pharmacology
- 1.00 Participation